Ridcovir
US 11,986,479, assigned to Pharsoln Inc, relates to medical technology, and is available for sale through IPApproach.
- US Patents
- 1 granted
- Assignee
- Pharsoln Inc
- Availability
- For Sale
Patents Included
Technology Highlights
- spike protein… located on the outer
- membrane protein… and the
- envelope protein… housing the intra-viral RNA protected by the
- nucleo-capsid protein.
- 3-Chymotrypsin-like protease (3CL pro) inhibited by Paxlovid/Pfizer
- RNA dependent RNA polymerase (RdRp) Molnupiravir/Merck
- Papain-like protease (PLpro) inhibited by Ridcovir/Naeger
- Helicase protease (H pro) inhibited by Ridcovir/Naeger
- Ridcovir is superior to Paxlovid as a Covid-19 treatment, because it provides symptom relief starting at 6 HOURS with symptom resolution by 11 HOURS after first dose of Ridcovir while Paxlovid takes 2 to 4 DAYS* before relief and resolution.
- Ridcovir may also eliminate incidence of Long Covid and Paxlovid rebound.
- Covid-19 is not going away; it will continue to mutate creating multiple variants requiring updated vaccines into the foreseeable future and better therapeutics than Paxlovid to actively treat it.
- Pfizer projects U.S. Paxlovid 2024's sales alone to exceed $1.6 BILLION
Overview
The 4 structural proteins make up the physical components of the round shaped virus. They include:
spike protein… located on the outer
membrane protein… and the
envelope protein… housing the intra-viral RNA protected by the
nucleo-capsid protein.
There are 4 essential non-structural proteins also called proteases of SARS-CoV-2. They are essential because they are needed for the replication/reproduction of the virus. These proteases are the drug treatment targets:
3-Chymotrypsin-like protease (3CL pro) inhibited by Paxlovid/Pfizer
RNA dependent RNA polymerase (RdRp) Molnupiravir/Merck
Papain-like protease (PLpro) inhibited by Ridcovir/Naeger
Helicase protease (H pro) inhibited by Ridcovir/Naeger
The INVENTION inhibits 2 essential enzymes not just 1 like Pfizer & Merck.
Request the Brokerage Marketing Package
Contact Justin Ehrlickman for full documentation, claim charts, and pricing on this opportunity.
Listing updated August 21, 2026
IPApproach lists patents and portfolios where the seller has not requested anonymity or confidentiality. Patent numbers link to public records on Google Patents.